Kaltsogianni Ourania, Dassios Theodore, Greenough Anne
Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.
Neonatal Intensive Care Centre, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Front Pediatr. 2023 Jul 26;11:1212074. doi: 10.3389/fped.2023.1212074. eCollection 2023.
Mechanical ventilation (MV), although life-saving, is associated with chronic respiratory morbidity in both preterm and term born infants. New ventilation modes have been developed with the aim of minimising lung injury. These include invasive and non-invasive respiratory support strategies, techniques for less invasive surfactant administration (LISA) and closed-loop automated oxygen control (CLAC) systems. Increasingly, newborn infants with signs of respiratory distress are stabilised on continuous positive airway pressure (CPAP) and receive LISA. Early CPAP when compared to mechanical ventilation reduced the incidence of BPD and respiratory morbidity at 18 to 22 months corrected age. Nasal intermittent positive pressure ventilation reduced treatment failure rates compared to CPAP, but not bronchopulmonary dysplasia (BPD). LISA compared with intubation and surfactant delivery reduced BPD, but there is no evidence from randomised trials regarding long-term respiratory and neurodevelopmental outcomes. Synchronisation of positive pressure inflations with the infant's respiratory efforts used with volume targeting should be applied for infants requiring intubation as this strategy reduces BPD. A large RCT with long term follow up data demonstrated that prophylactic high frequency oscillatory ventilation (HFOV) improved respiratory and functional outcomes at school age, but those effects were not maintained after puberty. CLAC systems appear promising, but their effect on long term clinical outcomes has not yet been explored in randomised trials. Further studies are required to determine the role of newer ventilation modes such as neurally adjusted ventilator assist (NAVA). All such respiratory support strategies should be tested in randomised controlled trials powered to assess long-term outcomes.
机械通气(MV)虽然能挽救生命,但与早产和足月出生婴儿的慢性呼吸系统疾病相关。已开发出新的通气模式,旨在将肺损伤降至最低。这些包括有创和无创呼吸支持策略、微创表面活性剂给药(LISA)技术和闭环自动氧控制(CLAC)系统。越来越多有呼吸窘迫迹象的新生儿通过持续气道正压通气(CPAP)得以稳定,并接受LISA治疗。与机械通气相比,早期使用CPAP可降低18至22个月矫正年龄时支气管肺发育不良(BPD)和呼吸系统疾病的发生率。与CPAP相比,鼻间歇正压通气降低了治疗失败率,但未降低支气管肺发育不良(BPD)的发生率。与插管和表面活性剂给药相比,LISA降低了BPD的发生率,但随机试验中没有关于长期呼吸和神经发育结局的证据。对于需要插管的婴儿,应将正压通气与婴儿呼吸努力同步并采用容量目标控制,因为该策略可降低BPD的发生率。一项具有长期随访数据的大型随机对照试验表明,预防性高频振荡通气(HFOV)可改善学龄期的呼吸和功能结局,但青春期后这些效果未得到维持。CLAC系统似乎很有前景,但随机试验尚未探讨其对长期临床结局的影响。需要进一步研究以确定神经调节通气辅助(NAVA)等新型通气模式的作用。所有此类呼吸支持策略都应在有足够能力评估长期结局的随机对照试验中进行测试。